Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q2 2024 · 10-Q
Revenue$72.00K$72.00K±0.0% vs Q2 2023 Net Income-$64.99M-$64.99MN/M vs Q2 2023 EPS Diluted-$1.02-$1.02N/M vs Q2 2023 Operating Income-$72,187,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$46,162,000N/M Margins · derivedOperating margin-100259.7%−17933.3 pt vs Q2 2023
Net margin-90268.1%−13791.7 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 8, 2024 · 39 d after period end